Three major differences between ruxolitinib and ruxolitinib cream

Ruxolitinib is a type of targeted oral therapy called a kinase inhibitor and is mainly used to treat conditions such as medium- and high-risk graft versus host disease, erythroblastosis and myelofibrosis, while ruxolitinib cream is a topical dermatological agent that is applied directly to the skin to treat eczema, vitiligo, atopic dermatitis and baldness. Although ruxolitinib and ruxolitinib cream are very different from each other, they are easily confused because they have a similar name. Changzhou Pharmaceutical Factory (CPF), one of the leading ruxolitinib suppliers in China, here analyzes the differences between them in terms of three major aspects to help people know more about them.

1. Indication

Ruxolitinib was approved by FDA in November 2011 and European Commission in August 2012 and is a kind of targeted drug with specific indications. It is used to treat patients who suffer from three types of disease, including steroid-refractory acute graft-versus-host disease, erythroblastosis, and moderate to high risk myelofibrosis (MF). But Ruxolitinib cream is in the development stage and fails to hit the market. It is therefore a topical medicine for the treatment of shinbone disease and baldness and does not yet have any approved indications. However, studies have demonstrated the clinical excellence of Ruxolitinib cream in the treatment of vitiligo, atopic dermatitis and severe baldness.

2. How to apply

Ruxolitinib is an oral kinase inhibitor that acts as a small molecule inhibitor of JAK1 and JAK2 protein kinases, and is the first drug approved by the FDA to treat myelofibrosis. But Ruxolitinib cream is a topical application cream which fundamentally differs from Ruxolitinib in the way it is used.

3. Side effect

Ruxolitinib has obvious side effects. The most common hematologic side effects associated with its use are reduced platelet count and anemia, and the most common non-hematologic side effects are petechiae, dizziness, and headache. However, Ruxolitinib cream is still in clinical trials, so its side effects are undetermined.

Media Contact
Company Name: Changzhou Pharmaceutical Factory
E-mail: Send an email
Call: +86 519 88821493
Address:NOPE. 518 East Laodong Road
Town: Changzhou
State: jiangsu
Country: China
Website: https://www.cz-pharma.com/

Comments are closed.